spiperone has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (60.87) | 18.7374 |
| 1990's | 8 (34.78) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bédard, PJ; Di Paolo, T; Gagnon, C | 1 |
| Bédard, PJ; Di Paolo, T; Rouillard, C | 1 |
| Lange, KW | 1 |
| Bruno, JP; Hadjiconstantinou, M; Neff, NH; Weihmuller, FB | 1 |
| Hadjiconstantinou, M; Neff, NH; Weihmuller, F | 1 |
| Cantrill, RC; Kurstjens, NP | 1 |
| Lajtha, A; Sershen, H; Wiener, HL | 1 |
| Bankiewicz, KS; Jacobowitz, DM; Joyce, JN; Kopin, IJ; Marshall, JF | 1 |
| Bédard, PJ; Di Paolo, T; Falardeau, P | 1 |
| Boyce, S; Clarke, CE; Crossman, AR; Robertson, RG; Sambrook, MA | 1 |
| Bhargava, HN; Perlow, MJ | 1 |
| Bédard, PJ; Bouchard, S; Boucher, R; Di Paolo, T; Falardeau, P | 1 |
| Bédard, PJ; Boucher, R; Di Paolo, T; Falardeau, P | 1 |
| Doudet, D; Guibert, B; Hantraye, P; Loc'h, C; Mazière, B; Mazière, M; Naquet, R; Riche, D; Stulzaft, O; Tacke, U | 1 |
| DeLanney, L; Irwin, I; Ison, PJ; Langston, JW; Peroutka, SJ; Ricaurte, G; Schlegel, JR | 1 |
| Freedman, R; Hoffer, B; Johnson, S; Jonsson, G; Mefford, I; Olson, L; Sundström, E | 1 |
| Hashim, A; Lajtha, A; Reith, ME; Sershen, H | 1 |
| Lahaye, D; Markstein, R | 1 |
| Erol, DD; Gnanalingham, KK; Hunter, AJ; Jenner, P; Marsden, CD; Smith, LA | 1 |
| Alexander, GM; Brainard, L; Gordon, SW; Grothusen, JR; Schwartzman, RJ | 1 |
| Gnanalingham, KK; Hunter, AJ; Jenner, P; Marsden, CD; Smith, LA | 1 |
| Borbely, K; Brooks, RA; Burns, RS; Cumming, P; Di Chiro, G; Gjedde, A; Wong, DF | 1 |
| Pope-Coleman, A; Schneider, JS; Tinker, JP | 1 |
1 review(s) available for spiperone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Deoxyglucose; Haplorhini; Humans; Levodopa; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Spiperone | 1987 |
22 other study(ies) available for spiperone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Autoradiography; Brain; Bromocriptine; Carbidopa; Catecholamines; Dopamine Agents; Female; Levodopa; Macaca fascicularis; Receptors, Dopamine; Spiperone | 1990 |
Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Brain; Brain Chemistry; Bromocriptine; Dopamine; Female; Homovanillic Acid; Kinetics; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Parkinson Disease, Secondary; Receptors, Dopamine; Spiperone | 1990 |
Behavioural effects and supersensitivity in the rat following intranigral MPTP and MPP+ administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Behavior, Animal; Injections; Male; MPTP Poisoning; Nervous System Diseases; Pyridinium Compounds; Rats; Rats, Inbred Strains; Receptors, Dopamine; Spiperone; Stereotyped Behavior; Substantia Nigra | 1990 |
Dopamine receptor plasticity following MPTP-induced nigrostriatal lesions in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; In Vitro Techniques; Kinetics; Male; Mice; Receptors, Dopamine; Spiperone; Substantia Nigra; Up-Regulation | 1990 |
Treatment with GM1 ganglioside reverses dopamine D-2 receptor supersensitivity induced by the neurotoxin MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; G(M1) Ganglioside; Kinetics; Male; Mice; Neurotoxins; Receptors, Dopamine; Receptors, Dopamine D2; Spiperone; Tritium | 1989 |
Systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine reduces the release of [3H]dopamine from rat striatal slices.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholine; Animals; Apomorphine; Corpus Striatum; Dopamine; Female; In Vitro Techniques; Kinetics; Neurotransmitter Agents; Rats; Rats, Inbred Strains; Spiperone | 1989 |
Dopamine D1 receptor and dopamine D2 receptor binding activity changes during chronic administration of nicotine in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Corpus Striatum; In Vitro Techniques; Male; Mice; Mice, Inbred BALB C; Nicotine; Pyridines; Receptors, Dopamine; Spiperone | 1989 |
Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Carotid Arteries; Corpus Striatum; Disease Models, Animal; Female; Functional Laterality; Infusions, Intra-Arterial; Macaca fascicularis; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Receptors, Dopamine D2; Spiperone; Tritium | 1986 |
Relation between brain dopamine loss and D2 dopamine receptor density in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Female; Homovanillic Acid; Kinetics; Macaca fascicularis; Nucleus Accumbens; Ovariectomy; Pyridines; Receptors, Dopamine; Receptors, Dopamine D2; Septal Nuclei; Spiperone | 1988 |
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on striatal dopamine receptors in C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Male; Mice; Mice, Inbred C57BL; Pyridines; Receptors, Dopamine; Spiperone | 1988 |
Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Benzazepines; Brain Chemistry; Dopamine; Dyskinesia, Drug-Induced; Female; Homovanillic Acid; Macaca fascicularis; Motor Activity; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Spiperone | 1988 |
Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Bromocriptine; Butyrophenones; Female; Kinetics; Levodopa; Macaca fascicularis; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Spiperone; Time Factors | 1986 |
"In vivo" visualization by positron emission tomography of the progressive striatal dopamine receptor damage occurring in MPTP-intoxicated non-human primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bromine; Corpus Striatum; Disease Models, Animal; Male; Papio; Parkinson Disease, Secondary; Pyridines; Radiography; Radioisotopes; Receptors, Dopamine; Spiperone; Tomography, Emission-Computed | 1986 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced dopamine D2 receptor hypersensitivity in the mouse is transient.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; In Vitro Techniques; Mice; Mice, Inbred C57BL; Pyridines; Receptors, Dopamine; Spiperone; Tritium | 1985 |
Electrophysiological and neurochemical correlates of the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Action Potentials; Animals; Brain Chemistry; Catecholamines; Dopamine; Male; Mice; Neurons; Norepinephrine; Phencyclidine; Pyridines; Spiperone; Time Factors | 1985 |
Reduction of dopamine uptake and cocaine binding in mouse striatum by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cocaine; Corpus Striatum; Depression, Chemical; Dopamine; Hydroxydopamines; In Vitro Techniques; Kinetics; Mice; Mice, Inbred BALB C; Pyridines; Spiperone; Synaptosomes | 1984 |
Neurochemical investigations in vitro with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in preparations of rat brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholine; Adenylyl Cyclases; Animals; Apomorphine; Brain Chemistry; Cerebral Cortex; Choline; Corpus Striatum; Dopamine; Electric Stimulation; In Vitro Techniques; Kinetics; Male; Mitochondria; Monoamine Oxidase; Norepinephrine; Pyridines; Rats; Spiperone | 1984 |
Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Binding, Competitive; Callithrix; Dopamine Agonists; Ergolines; In Vitro Techniques; Male; Parkinson Disease, Secondary; Quinpirole; Radioligand Assay; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Spiperone | 1995 |
Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-dopa treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Benzazepines; Brain; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Receptors, Dopamine D1; Receptors, Dopamine D2; Spiperone | 1993 |
Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Benzazepines; Brain; Callithrix; Corpus Striatum; Female; Male; Mazindol; Parkinson Disease, Secondary; Receptors, Dopamine D1; Receptors, Dopamine D2; Spiperone; Tissue Distribution | 1993 |
NMSP binding to dopamine and serotonin receptors in MPTP-induced parkinsonism: relation to dopa therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Antiparkinson Agents; Binding Sites; Cerebellum; Dopamine Antagonists; Humans; Levodopa; Male; Models, Chemical; Occupational Diseases; Parkinson Disease, Secondary; Putamen; Receptors, Dopamine; Receptors, Serotonin; Severity of Illness Index; Spiperone; Tomography, Emission-Computed | 1999 |
Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Binding Sites; Dopamine Agents; Dopamine Antagonists; Dopamine Uptake Inhibitors; G(M1) Ganglioside; Mazindol; Neostriatum; Parkinsonian Disorders; Radioligand Assay; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Recovery of Function; Saimiri; Spiperone; Synapses | 2000 |